Navigation Links
Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709

An oral formulation of iclaprim has successfully completed three Phase I trials: a radiolabelled ADME study (absorption, distribution, metabolism and excretion), a Phase I bioavailability trial with a solution and one with a capsule formulation. Arpida believes that the availability of an oral formulation could potentially fulfil an important clinical medical need for the treatment of serious bacterial infections, particularly those caused by MRSA. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge and outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's third most advanced programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against 611 pneumococcal clinical isolates from Europe, the USA and Asia irrespective of the mechanisms of resistance to currently used drugs. Arpida received authorisation to enter first-in-man studies with AR-709 in the UK in the second half of 2006.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating MRSA in preclinical models of skin infection and nasal carriage.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed i
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Arpida adds novel antibiotic AR-2474 to its preclinical pipeline
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Arpida Announces Promising Results First Man Studies With
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive Medicine ... leader in the field of infertility, presents new ... embryonic screening. The research abstract, released during the ... Medicine (ASRM) meeting in Honolulu, Hawaii ... single gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014  Paper ... products, has developed APLS ® Body Guard ... minimizes the spread of bacteria and virus while ... APLS Body Guard Bio features a rugged, external ... edges that create a leak-proof inner chamber that ...
(Date:10/22/2014)... A new report by Allied ... Form, End user, Application and Geography) - Size, Share, ... Opportunities, Segmentation and Forecast, 2013 - 2020", considers commercial ... key trends tracked, it is anticipated that the market ... 2020, registering a CAGR of 6.2% from 2014 to ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4
... (Nasdaq: BIOD ) today announced positive top-line ... product candidates, BIOD-123 and BIOD-125 -- two proprietary ultra-rapid-acting ... BIOD-123 and BIOD-125 achieved the Company,s target pharmacokinetic, pharmacodynamic ... BIOD-123 favored as lead product candidate to advance to ...
... 13, 2012  AATAC, AACSA, and SKYROCK retailers can expect ... sale to the general public. A marketing and distribution ... retailers to participate in the resale of this product ... counter top space alongside such products as 5-Hour Energy, ...
Cached Medicine Technology:Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 2Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 3Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 4Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 5Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations 6Strategic Product Deployment Announcement: Clotamin 2
(Date:10/22/2014)... 2014 Medical Solutions , ... happy to announce that our co-founder and CFO, ... Analysts’ Staffing 100 for 2014. Anderson was also ... influential people in the staffing industry,” in 2013.     ... 13th-largest healthcare staffing company in the U.S., was ...
(Date:10/22/2014)... October 22, 2014 Shriners Hospitals for ... will change the current location of Shriners Hospitals for ... Limestone across from the University of Kentucky Albert B. ... ambulatory care center, owned and operated by Shriners Hospitals ... needs of children and their families well into the ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... pneumococcal pneumonia -- a common bacterial pneumonia that can ... issue of Mayo Clinic Women's HealthSource is spreading the ... this form of pneumonia and reduces the serious complications ... of the vaccine, or may not know that they ...
... For some people, the most convenient approach is a ... to help burn calories and increase cardiovascular fitness.// ... health, some aerobic exercise machines may be more suited ... Health Letter covers some options: ,Treadmills: Generally ...
... been selected by the federal Department of Health and ... initiative, called “Own your future” carries a potent message; ... residents. ,Gov Perry while announcing the details of ... Texans age 45 to 65 to begin thinking about ...
... the capital, taking the toll to 25 Saturday while 95 ... number of dengue cases in Delhi has now risen to ... disease was 25-year-old Farahan of Delhi. She was brought to ... and died in the early hours of Saturday, said medical ...
... in recent studies that they are very beneficial to cardiac ... the heart according to the results of a study published ... 2006. ,Studies conducted have shown that PUFA helps to ... seen in cardiac function which usually reflects a bad prognosis, ...
... of Utah’s Huntsman Cancer Institute have discovered a new target ... is implicated in 85 percent of colon cancer cases. // ... – a molecule called C-Terminal Binding Protein (CTBP) researchers were ... in the adenomatous polyposis coli (APC) gene. ,In ...
Cached Medicine News:Health News:Home Is Where the Gym Is 2Health News:Dengue Claims Yet Another Victim in Delhi 2Health News:A New Way to Treat Colon Cancer? 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: